

CURRICULUM VITAE

ANDREW JOHN GLEASON
MB BS (HONS), BSC, CERT. OLD AGE PSYCH., FRANZCP, AFRACMA

December 2020

PERSONAL DETAILS

Postal address: PO Box 542, Newtown NSW 2042

Email: dr.andrewgleason@tutanota.com

ACADEMIC AND PROFESSIONAL QUALIFICATIONS

Member of the Faculty of Consultation-Liaison Psychiatry, Royal Australian and New Zealand College of Psychiatrists (2015)

Associate Fellow of the Royal Australasian College of Medical Administrators (2014)

Member of the Faculty of Psychiatry of Old Age, Royal Australian and New Zealand College of Psychiatrists (2014)

Certificate in Psychiatry of Old Age, Royal Australian and New Zealand College of Psychiatrists (2014)

Fellowship of the Royal Australian and New Zealand College of Psychiatrists (2012)

Bachelor of Medicine and Bachelor of Surgery with Honours
The University of Sydney (2005)

Bachelor of Science in Biology (Molecular Genetics)
The University of Sydney (2001)

AHPRA registration as a Medical Practitioner: MED0001214499

EMPLOYMENT HISTORY

Current positions

Senior Staff Specialist in Consultation-Liaison Psychiatry, Concord Hospital, Sydney (from January 2020)

Clinical Lead, Department of Consultation-Liaison Psychiatry, Concord Hospital (from August 2020)

Consultant Old Age and Neuro-psychiatrist, Northern Tasmania Huntington's Disease Service and Older Persons' Mental Health Service, Launceston (funded by Rural Health Outreach Fund) (from May 2014)

Honorary Principal Research Fellow, Melbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health, the University of Melbourne (from March 2018)

Previous positions

July 2016 to January 2020

Head, Aged Psychiatry Research, Alfred Health, Melbourne

January 2015 to January 2020

Consultant Old Age Psychiatrist, Cognitive Decline and Memory Service, Alfred Health, Melbourne

January 2017 to January 2020

Consultant Neuropsychiatrist, Comprehensive Epilepsy Service and Movement Disorders Service, Alfred Health, Melbourne

January 2015 to January 2020

Visiting Medical Officer in Aged Psychiatry, Clinical Trials Research, Alfred Health, Melbourne

July 2016 to January 2020

Senior Specialist in Neuropsychiatry, Statewide Progressive Neurological Diseases Service, Calvary Healthcare Bethlehem, Melbourne

November 2017 to January 2020

Consultation-Liaison Neuropsychiatrist and Old Age Psychiatrist to Cabrini Hospital, Melbourne

November 2013 to August 2016

Consultation-Liaison Neuropsychiatrist and Old Age Psychiatrist at John Fawkner and Brunswick Private Hospitals

July 2013 to August 2016

Consultant Old Age Psychiatrist in private practice at Albert Road Clinic, Melbourne

December 2014 to December 2017

Honorary Fellow, Department of Psychiatry, the University of Melbourne

June 2012 to November 2014

Consultant Old Age Psychiatrist, Melbourne Health

February 2011 to June 2012

Senior Neuropsychiatry Registrar, Neuropsychiatry Unit, Royal Melbourne Hospital

August 2009 to February 2011:

Senior Psychiatry Registrar, St Vincent's Health, Melbourne

May 2007 to July 2009:

Psychiatry Registrar, Sydney South West Area Health Service

Feb 2006 to April 2007:

Hospital Medical Officer, The Alfred Hospital, Melbourne

Jan 2005 to Jan 2006:

Intern, Nepean Hospital, Sydney

AWARDS

2020: RANZCP Foundation Early Career Research Grant

2015: RANZCP Faculty of Psychiatry of Old Age Psychiatric Trainee Prize for Scholarly Project

2013: Membership of the Melbourne Medical School Academy of Teachers (awarded for contributions to medical student teaching), the University of Melbourne

2004: Harry J Clayton Memorial Prize for Medicine and Clinical Medicine, the University of Sydney

2003: Australian Medical Association J.G. Hunter Research Fellowship

2002: Royal College of Pathologists of Australasia Scholarship in Pathology for Medical Schools

2002: John Flood Memorial Scholarship, the University of Sydney Faculty of Medicine

CLINICAL TRIALS EXPERIENCE

Principal investigator:

An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression (Janssen SUSTAIN-3; TRD3008)

A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer's Disease (Eisai Mission AD, E2609-G000-301)

A Phase 2 Study of BIIB092 in Participants with Early Alzheimer's Disease (Biogen TANGO; 251AD201)

An Extension Study of ANAVEX2-73 in Patients with Mild to Moderate Alzheimer's Disease (Anavex 2-73-003)

A Multinational, Multi-center, Randomized, Double-blind, Active comparator, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Donepezil Transdermal Patch in Patients with Alzheimer's Disease (iCure IPI-003)

An Open-label, Long-term Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression (Janssen SUSTAIN-2; ESKETINTRD3004)

A Multicenter, Open-Label, Long-Term Extension of Phase III Studies (BN29552/BN29553) of Crenezumab in Patients with Alzheimer's Disease (Roche CREAD, BN29552)

A Phase III, Multicentre, Randomized, Double-Blind Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Crenezumab in Patients with Prodromal to Mild Alzheimer's Disease (Roche CREAD, BN29552)

Randomized, Double-Blind, Placebo Controlled, Multi-Center Registration Trial to Evaluate the Efficacy and Safety of TTP488 in Patients with Mild Alzheimer's disease Receiving Acetylcholinesterase Inhibitors and/or memantine (VTV Steadfast; TTP488-301)

Open Label Extension Study for Continued Safety and Efficacy Evaluation of Azeliragon in Patients with Mild Alzheimer's Disease (VTV Steadfast; TTP488-303)

A Phase 3, double-blind, randomised study of RVT-101 versus placebo when added to existing stable donepezil treatment in subjects with mild to moderate Alzheimer's disease (Axovant Mindset, RVT-101-3001)

Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo (Eli Lilly LZAX, H8A-MC-LZAX(c))

Sub-investigator:

Randomised, double-blind, parallel-group, placebo-controlled study of Lu AE58054 in patients with mild-moderate Alzheimer's disease treated with an acetylcholinesterase inhibitor; Study 3 (Lundbeck Starbright; 14863A)

A Phase IIa Study of ANAVEX2-73 Adaptive-Trial-Design with Repeated Doses, Maximum Tolerated Dose Finding, Pharmacodynamic Investigation and Bioavailability Evaluation in Patients with Mild to Moderate Alzheimer's Disease with a 52 Week Open Label Follow-Up Period (Anavex 2-72-002; Anavex 2-73)

A 26-Week Extension Study of the Safety and Clinical Effects of EVP-6124 in Subjects with Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication (EnVivo EVP-6124-026; EVP-6124)

A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients with Manifest Huntington's Disease (F. Hoffman-La Roche Ltd, BN40423)

A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Single and Multiple Doses of AL002 in Healthy Participants and in Participants with Mild to Moderate Alzheimer's Disease. (Alector AL002-1).

A Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled 48-week Safety and Efficacy trial of ANAVEX2-73 for the Treatment of Early Alzheimer's Disease (Anavex2-73-004)

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of MTAU9937A (RO7105705) in Patients with Prodromal to Mild Alzheimer' Disease (Genentech GN39763; Tauriel)

Deferiprone to Delay Dementia (The 3D Study): a clinical proof of concept study (DEF001)

A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Mild to Moderate Alzheimer's Disease (Cognition Therapeutics; COG0201)

A Multicentre, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients with Huntington's Disease (WAVE Life Sciences, WVE-HDSNP1-001)

A Multicentre, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120102 Administered Intrathecally in Patients with Huntington's Disease (WAVE Life Sciences, WVE-HDSNP2-001)

Enroll-HD: A Prospective Registry Study in a Global Huntington's Disease Cohort

A randomised controlled trial of theta burst stimulation for treatment of cognitive impairment in mild to moderate Alzheimer's disease. Hoy K, Fitzgerald P, Gleason A. (Investigator-initiated project) Funded by: Mason Foundation National Medical Program, 2018, AU\$100,000

PUBLICATIONS

Books

Castle D, Bassett, King J, Gleason A. *A Primer in Clinical Psychiatry*. 2nd ed. Chatswood: Churchill Livingstone; 2013

Peer-reviewed journal articles

Gleason A, Bush AI. Iron and ferroptosis as therapeutic targets in Alzheimer's disease. *Neurotherapeutics*. 2020, *in press*.

Gleason A, Ayton S, Bush AI. Unblinded by the light: ARIA in Alzheimer's clinical trials. *European Journal of Neurology*. 2020; doi: 10.1111/ene.14484. Epub ahead of print.

Gleason A, Lewis M, Lee SM, Macfarlane S. A preliminary investigation of domestic squalor in people with a history of alcohol misuse: neuropsychological profile and hoarding behaviour – an opportunistic observational study. *International Psychogeriatrics*. 2015; 27(11): 1913-1918.

King J, Hill K, Gleason A. All the world's a stage: evaluating psychiatry role-play based learning for medical students. *Australasian Psychiatry*. 2015; 23(1): 76-79.

Gleason A, Hayhow B, Walterfang M, Evans A, Mocellin R, Gates P, Velakoulis D. Neuropsychiatric symptoms as the presenting feature of acquired hepatocerebral degeneration. *Australian and New Zealand Journal of Psychiatry*. 2014; 48(10): 959-960.

Gleason A, Hayhow B, Emmanuel J, Gaillard F. Cerebral amyloid angiopathy presenting with neuropsychiatric symptoms. *Australian and New Zealand Journal of Psychiatry*. 2014; 48(8): 779-80.

Velakoulis D, Gleason A, Hayhow B, McNeil P, Gaillard F. Frontal meningioma mimicking relapse of schizophrenia. *Australian and New Zealand Journal of Psychiatry*. 2014; 48(5): 486-487.

Hassan I, Shing C, Bajraszewski C, Gleason A, Hayhow B, Velakoulis D. Osmotic demyelination syndrome: an under-recognised cause of delirium? *Australian and New Zealand Journal of Psychiatry*. 2013; 21(1): 76-9.

Sketcher B, London, J, Gleason, A. Evidence-based medicine: a position statement is needed. *Australasian Psychiatry*. 2013; 21(1): 76-77.

Gleason A, Castle D. Adult Attention-Deficit Hyperactivity Disorder and Bipolar Disorder. *Advances in Psychiatric Treatment*. 2012; 18(3): 198-204. (Awarded Editor's Pick for the May 2012 issue)

Gleason A, Castle D, Piterman L, Jones K. Bipolar Disorder. *Check Independent Learning Program for GPs*. Unit 468, March 2011.

Turnbull F, Neal B, Ninomiya T, Algert C, Arima H, Barzi F, Bulpitt C, Chalmers J, Fagard R, Gleason A, Heritier S, Li N, Perkovic V, Woodward M, MacMahon S. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. *British Medical Journal* 2008; 336(7653):1121-3

Graham IS, Gleason AJ, Keogh GW, Paltridge D, Rogers IR, Walton M, De Paola C, Singh J and McGrath BP. Australian Curriculum Framework for Junior Doctors. *Medical Journal of Australia* 2007; 186 (7): S14-S19.

Gleason AJ, Daly JO, Blackham RE. Prevocational Medical Training and the Australian Curriculum Framework for Junior Doctors: A Junior Doctor Perspective. *Medical Journal of Australia* 2007; 186 (3): 114-116